Finance

Lists
1KVUE:BIT
Kenvue Inc
€16.22
-0.52%
(-0.085) 1D
Aug 27, 9:00:23 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1KVUE...
Mkt. cap
36.66B
Avg. vol.
22.00
Volume
0.00
52-wk high
€17.79
52-wk low
€12.13
No. of employees
22K
Mkt. cap
36.66B
Avg. vol.
22.00
Volume
0.00
52-wk high
€17.79
52-wk low
€12.13
No. of employees
22K
News stories
From web sources and news partners
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEO-
Employees21.9K
FoundedFeb 23, 2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.76B
3.78B
3.91B
3.96B
Cost of goods sold
1.53B
1.63B
1.60B
1.64B
Cost of revenue
1.53B
1.63B
1.60B
1.64B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.51B
1.51B
1.45B
1.54B
Operating expense
1.51B
1.48B
1.46B
1.54B
Total operating expenses
3.04B
3.11B
3.06B
3.19B
Operating income
726.00M
674.00M
845.00M
768.00M
Other non operating income
10.00M
7.00M
-
1.00M
EBT including unusual items
526.00M
427.00M
672.00M
598.00M
EBT excluding unusual items
623.00M
574.00M
750.00M
667.00M
Income tax expense
128.00M
97.00M
198.00M
142.00M
Effective tax rate
24.33%
22.72%
29.46%
23.75%
Other operating expenses
1.00M
-30.00M
11.00M
6.00M
Net income
398.00M
330.00M
474.00M
456.00M
Net profit margin
10.57%
8.73%
12.13%
11.53%
Earnings per share
0.28
0.27
0.32
0.31
Interest and investment income
14.00M
11.00M
11.00M
13.00M
Interest expense
-107.00M
-109.00M
-106.00M
-103.00M
Net interest expenses
-93.00M
-98.00M
-95.00M
-90.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
867.00M
713.00M
988.00M
913.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps